Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.

Xiangling ChuHuiping QiangMengqing XieXing LiJing ZhaoYan WuJuan ZhouJinyan YeChao ZhaoChaonan HanTianqing ChuChunxia Su

Published in: Cancer immunology, immunotherapy : CII (2021)

Our retrospective study provides clinical evidence that front line of ICIs-based therapy is also worth considering for the treatment to improve survival outcomes of patients with HER2-mutant lung adenocarcinoma.

Keyphrases

stem cells
replacement therapy
mesenchymal stem cells
wild type
double blind